Chitsaz Ahmad, Tolou-Ghamari Zahra, Ashtari Fereshteh
Department of Neurology, Faculty of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran.
Int J Prev Med. 2013 May;4(Suppl 2):S347-52.
According to the international reports, brain stroke is the main reason of death and disability. In ischemic stroke, early and precise classification of patients who may profit from conflicting finest therapeutic interference is necessary if enhanced effects in terms of survival are to be talented. Due to uncomplicated, easy performance, and inexpensive method the aim of this preliminary study was to investigate changes related to biochemical and hematological variables in patients with stroke.
A cross-sectional study located at the neurology ward of the Ayatolah Kashani and Alzahra Hospitals' (conducted to Isfahan Neurosciences Research Center) was carried out on fifty patients (females; n = 20 and males; n = 30) between April 1, 2012 and September 31, 2012. The data from subjects' records were taken for analyzing variables. The statistical analysis of d-base was performed using (SPSS) for windows.
Analysis of available data showed that with a mean of 182.4 mg/dl, blood sugar (BS) ranged from 75 to 300 mg/dl (n = 15/50). The changes in hemoglobin (Hgb) (mean 4.6 g/dl, n = 27/50), platelet (mean 210, 653/mm(3), n = 26/50) and lymphocyte (Lymph) (mean 37, n = 26/50) seems to be significant. The mean age of females was 76 years (ranged 46-93 years). The mean age of males was 70 years (ranged 31-90 years). Information related to previous drug history was available only in 24 patients. In 5 out of 22 cases ischemic heart disease (IHD) were positive. In 8 out of 29 cases, diabetes mellitus was positive. In 5 out of 28 cases, hypertension (HTN) was positive. In the four patients both IHD and HTN were positive.
Any considerable alter in patients' biochemical and hematological figures (BS, Hgb, Plt and Lymph) may necessitate further attention related to inter- and intra-individual variability in clinical supervision and drug's assortment. Therefore, success in treatment could be achieved by the close management of clinical, biochemical, hematological, and pharmacological manifestation. To reduce disability, mortality, and morbidity in Iranian stroke population further clinical studies are needed to correlate drugs and laboratory markers to associated clinical events in order.
根据国际报告，脑卒中是死亡和残疾的主要原因。在缺血性卒中中，若要在生存方面取得更好的效果，就必须对可能从相互矛盾的最佳治疗干预中获益的患者进行早期准确分类。由于方法简单、操作简便且成本低廉，本初步研究的目的是调查脑卒中患者生化和血液学变量的变化。
于2012年4月1日至2012年9月31日在阿亚图拉·卡沙尼医院和阿尔扎赫拉医院（由伊斯法罕神经科学研究中心开展）的神经科病房对50例患者（女性20例，男性30例）进行了横断面研究。从受试者记录中获取数据以分析变量。使用适用于Windows的（社会科学统计软件包）对数据库进行统计分析。
对现有数据的分析表明，血糖（BS）平均为182.4mg/dl，范围为75至300mg/dl（n = 15/50）。血红蛋白（Hgb）（平均4.6g/dl，n = 27/50）、血小板（平均210,653/mm³，n = 26/50）和淋巴细胞（Lymph）（平均37，n = 26/50）的变化似乎具有显著性。女性的平均年龄为76岁（范围46 - 93岁）。男性的平均年龄为70岁（范围31 - 90岁）。仅24例患者有既往用药史信息。22例中有5例缺血性心脏病（IHD）呈阳性。29例中有8例糖尿病呈阳性。28例中有5例高血压（HTN）呈阳性。4例患者IHD和HTN均呈阳性。
患者生化和血液学指标（BS、Hgb、Plt和Lymph）的任何显著变化可能需要在临床监测和药物选择中进一步关注个体间和个体内的变异性。因此，通过密切管理临床、生化、血液学和药理学表现可实现治疗成功。为降低伊朗卒中人群的残疾、死亡率和发病率，需要进一步开展临床研究，以便将药物和实验室指标与相关临床事件依次关联起来。
